Patent ID: 8758810
Filing Date: 2014-06-24
Classification: A61K,A61P

Abstract:
1. A targeted liposome comprising one or more phosphatidylcholines selected from the group consisting of DMPC, DPPC, POPC, and DSPC, an N-(ω) -dicarboxylic acid-derivatized phosphatidyl ethanolamine, a targeting factor-modified N-(ω)-dicarboxylic acid-derivatized phosphatidyl ethanolamine, an encapsulated drug, and at least one additional lipid, which is cholesterol, wherein the mol % of the phosphatidylcholines is 30-70 mol %, the cholesterol is 30-60 mol %, and the total of the N-(ω)-dicarboxylic acid-derivatized phosphatidyl ethanolamine plus targeting factor-modified N-(ω)-dicarboxylic acid-derivatized phosphatidyl ethanolamine is 2-12 mol %, and where the total mol % of the phosphatidylcholines, cholesterol, and the derivatized phosphatidylethanolamines is 100%; wherein the targeting factor-modified N-(ω)-dicarboxylic acid-derivatized phosphatidyl ethanolamine comprises transferrin linked to a second N-(ω)-dicarboxylic acid-derivatized phosphatidyl ethanolamine; and wherein the N-(ω)-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 1,  and the second N-(ω)-dicarboxylic acid-derivatized phosphatidyl ethanolamine is represented by Formula 3, wherein the liposome does not comprise a non-derivatized phosphatidyl ethanolamine, egg phosphatidylcholine, or a hydrophilic polymer used to enhance the circulatory half-life of liposomes.